IVM is not a viable option to treat COVID-19 patients. IVM did not have an effect on AEs or severe AEs. In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease. Subgroups by severity of COVID-19 or RoB were mostly consistent with main analyses all-cause mortality in three RCTs at high RoB was reduced with IVM. AEs, severe AE and viral clearance were similar between IVM and controls (all outcomes: low QoE). IVM did not reduce all-cause mortality vs. COVID-19 disease severity was mild in 8 RCTs, moderate in one RCT, and mild and moderate in one RCT. Controls were standard of care in five RCTs and placebo in five RCTs. with quality of evidence (QoE) evaluated using GRADE methodology. Inverse variance random effect meta-analyses were performed. Risk of bias (RoB) was evaluated using Cochrane RoB 2♰ tool. Secondary outcomes included viral clearance and severe AEs. Primary outcomes were all-cause mortality, length of stay (LOS), and adverse events (AE). Published and preprint randomized controlled trials (RCTs) assessing IVM effects on COVID-19 adult patients were searched until Main five engines. Trejo G, Ley S (2016) Federalismo, drogas y violencia: Por qué el conflicto partidista intergubernamental estimuló la violencia del narcotráfico en México.We systematically assessed benefits and harms of the use of ivermectin (IVM) in COVID-19 patients. Rydell P, Everingham S (1994) Controlling cocaine: supply versus demand programs. Room R, Fischer B, Hall W, Lenton S, Reuter P (2008) Cannabis policy: moving beyond stalemate. Romero V, Magaloni B, Díaz-Cayeros A (2015) The Mexican war on drugs: crime and the limits of government persuasion.
DOPEWARS VER 2.2 SERIES
Picatto P (2003) Estadísticas del crimen en México: Series históricas, 1901–2001. Magaloni B, Diaz Calleros A, Matanock A, Romero V (2015) Living in fear: the dynamics of extortion in Mexico's criminal insurgency. Kilmer B, Pacula R (2009) Estimating the size of the global drug market: a demand-side approach. INEGI (2014) Instituto Nacional de Estadísticas Geografía y Censos. Heinle K, Rodríguez Ferreira O, Shirk D (2017) Drug violence in inegi: data and analysis through 2016. Guerrero Eduardo (2011) La Raíz de la Violencia. At Įscalante F (2009) El homicidio en México entre 1990 y 2007: aproximación estadística. Consumo de drogas: prevalencias globales, tendencias y variaciones estatales. Ver, p45ĮNCODAT (2017) Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco 2016-2017. En Ĭunningham J, Maxwell J, Campollo O, Cunningham K, Mu Liu L, Lin Lin H (2010) Proximity to the US-Mexico border: a key to explaining geographic variation in US methamphetamine, cocaine and heroin purity. Rand Corporation, Santa MonicaĬELIV (2014) Delito, marginalidad y desempeño institucional en la Argentina: Resultados de la encuesta de presos condenados. RAND Corporation, Santa MonicaĬaulkins J, Reuter P, Iguchi M, Chiesa J (2005) How goes the “war on drugs”?: an assessment of U.S. Center for Global Development, Washington, DCĬaulkins J (2005) Price and Purity Analysis for Illicit Drug: Data and Conceptual Issues. Ĭastillo JC, Mejía D, Restrepo P (2014) Scarcity without leviathan: the violent effect of cocaine supply shortages in the Mexican drug war, Center for the Global Development working paper no 356. Oxford University Press, New YorkĬASEDE (2016) Atlas de la Seguridad y la Defensa de México 2016. Plaza y Janes, México Cityīergman M (2018) More money more crime: prosperity and rising crime in Latin America.
Astorga L (2005) El siglo de las drogas: el narcotráfico, del Porfiriato al nuevo milenio.
0 kommentar(er)
